PL365596A1 - Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses - Google Patents

Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses

Info

Publication number
PL365596A1
PL365596A1 PL01365596A PL36559601A PL365596A1 PL 365596 A1 PL365596 A1 PL 365596A1 PL 01365596 A PL01365596 A PL 01365596A PL 36559601 A PL36559601 A PL 36559601A PL 365596 A1 PL365596 A1 PL 365596A1
Authority
PL
Poland
Prior art keywords
necroses
tumours
plaques
imaging
representation
Prior art date
Application number
PL01365596A
Other languages
Polish (pl)
Inventor
Johannes Platzek
Peter Mareski
Ulrich Niedballa
Bernd Raduchel
Hanns-Joachim Weinmann
Bernd Misselwitz
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10040380A external-priority patent/DE10040380B4/en
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of PL365596A1 publication Critical patent/PL365596A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PL01365596A 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses PL365596A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10040380A DE10040380B4 (en) 2000-08-11 2000-08-11 MRI contrast agent for visualization of plaque, lymph nodes, infarcted and necrotic tissue or both necrosis and tumors, comprising perfluoroalkylated metal complex having specific micelle forming properties
PCT/EP2001/008498 WO2002013874A2 (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses

Publications (1)

Publication Number Publication Date
PL365596A1 true PL365596A1 (en) 2005-01-10

Family

ID=7652860

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01365596A PL365596A1 (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses

Country Status (26)

Country Link
EP (1) EP1307236A2 (en)
JP (1) JP2004506025A (en)
KR (1) KR20030022387A (en)
CN (1) CN1469757A (en)
AR (1) AR034139A1 (en)
AU (2) AU7754901A (en)
BG (1) BG107542A (en)
BR (1) BR0113188A (en)
CA (1) CA2419223A1 (en)
CZ (1) CZ2003392A3 (en)
DE (1) DE10066210B4 (en)
EE (1) EE200300061A (en)
HR (1) HRP20030173A2 (en)
HU (1) HUP0300736A3 (en)
IL (1) IL154385A0 (en)
MX (1) MXPA03001287A (en)
NO (1) NO20030604L (en)
NZ (1) NZ523932A (en)
PL (1) PL365596A1 (en)
RU (1) RU2290206C2 (en)
SK (1) SK1572003A3 (en)
TW (1) TWI296931B (en)
UA (1) UA82642C2 (en)
WO (1) WO2002013874A2 (en)
YU (1) YU10603A (en)
ZA (1) ZA200301949B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10231799B4 (en) * 2002-07-10 2006-10-05 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast agents in MR imaging for the presentation of intravascular thrombi
US7344704B2 (en) 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
DE102005008309A1 (en) * 2005-02-17 2006-08-24 Schering Ag Pharmaceutical agents containing fluoroalkyl-containing metal complexes and epothilones
DE102006021495A1 (en) * 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Use of metal chelate containing perfluorinated alkyl-residue, chelator-residue and metal ion equivalent to the atomic number, for the production of diagnostic agent for representation of amyloid-containing plaques
US7887835B2 (en) * 2006-09-19 2011-02-15 Fujifilm Corporation Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound
DE102006049821A1 (en) 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft New, well tolerated metal chelates, for use as radiodiagnostic, radiotherapeutic or NMR and X-ray diagnostic agents, contain chelator and perfluorinated polyethylene glycol residues
DE102007015598A1 (en) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Use of fluorochemical compounds for diagnostic purposes using imaging techniques
JP2011190183A (en) * 2010-03-11 2011-09-29 Noguchi Institute Fluorous sugar-bonded crown ether derivative
US9976072B2 (en) 2014-03-26 2018-05-22 Chevron U.S.A. Inc. Multicarboxylate compositions and method of making the same
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
WO2018052037A1 (en) 2016-09-14 2018-03-22 ダイキン工業株式会社 Branched fluorine-containing compound
CN110035996B (en) 2016-11-28 2022-08-09 拜耳医药股份公司 Novel highly relaxant gadolinium chelates for magnetic resonance imaging
KR20210095168A (en) 2018-11-23 2021-07-30 바이엘 악티엔게젤샤프트 Formulation of Contrast Media and Method for Preparing Same
CN109867635A (en) * 2019-02-14 2019-06-11 华东师范大学 A kind of T1 type micella magnetic resonance imaging contrast and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19603033A1 (en) * 1996-01-19 1997-07-24 Schering Ag Perfluoroalkyl-containing metal complexes, processes for their preparation and their use in NMR diagnostics
JPH10112939A (en) * 1996-10-07 1998-04-28 Nec Corp Power switching circuit
DE19729013A1 (en) * 1997-07-03 1999-02-04 Schering Ag Oligomeric, perfluoroalkyl-containing compounds, processes for their preparation and their use in NMR diagnostics
US6019959A (en) * 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis

Also Published As

Publication number Publication date
CA2419223A1 (en) 2003-02-11
ZA200301949B (en) 2004-12-14
EE200300061A (en) 2004-12-15
AU2001277549B2 (en) 2007-02-08
MXPA03001287A (en) 2003-10-06
HUP0300736A2 (en) 2003-09-29
KR20030022387A (en) 2003-03-15
CN1469757A (en) 2004-01-21
EP1307236A2 (en) 2003-05-07
BG107542A (en) 2003-09-30
NZ523932A (en) 2007-07-27
HRP20030173A2 (en) 2005-04-30
DE10066210B4 (en) 2008-02-28
CZ2003392A3 (en) 2003-09-17
RU2290206C2 (en) 2006-12-27
SK1572003A3 (en) 2003-10-07
AU7754901A (en) 2002-02-25
WO2002013874A2 (en) 2002-02-21
BR0113188A (en) 2003-06-24
AR034139A1 (en) 2004-02-04
NO20030604D0 (en) 2003-02-07
WO2002013874A8 (en) 2002-06-13
HUP0300736A3 (en) 2010-01-28
UA82642C2 (en) 2008-05-12
YU10603A (en) 2006-05-25
IL154385A0 (en) 2003-09-17
TWI296931B (en) 2008-05-21
JP2004506025A (en) 2004-02-26
NO20030604L (en) 2003-04-11

Similar Documents

Publication Publication Date Title
IL259724B (en) 40-o-(2-hydroxyethyl)-rapamycin for use in combination with an aromatase inhibitor for the treatment of breast tumors
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
PT1757606E (en) Xanthinderivatives for use as medical agents and the preparation thereof
IL154385A0 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
IL158985A0 (en) Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
EP1465997A4 (en) Use of biomolecular targets in the treatment and visualization of tumors
AU2001277549A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
ITMI991764A0 (en) NEW METALLIC COMPLEXES USABLE IN CATALYSIS FOR THE CO-POLYMERIZATION OF ALPHA-OLEFINS
HUP0401903A3 (en) Improved use of et-743 in cancer thereapy
HUP0400997A3 (en) Multidentate aza ligands able to complex metal ions and the use thereof in diagnostics and therapy
EP1661548A4 (en) Agent for eliminating singlet oxygen and composition using the same
EP1390689A4 (en) Reducing coherent artifacts in an interferometer
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
IL159879A0 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
AU2003281146A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of intravascular thrombes
AU2003233431A8 (en) Protamine-adenoviral vector complexes and methods of use
HUP0400262A3 (en) Glycopeptides, their preparation and use in the treatment of multiple sclerosis
IL152388A0 (en) Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione
EP1383543A4 (en) Use of biomolecular targets in the treatment and visualization of brain tumors
GB0022081D0 (en) Pyrazolone lanthanide complexes
GB0106316D0 (en) Apparatus for use in the treatment of hair
EP1677958A4 (en) Slurries containing iron compounds used in the casting of metals
IL146655A0 (en) The use of leptin in fertility
AU2002354738A1 (en) Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)